
CME Group (CME) Stock Forecast & Price Target
CME Group (CME) Analyst Ratings
Bulls say
CME Group is well positioned for durable fundamental growth because its exchange model combines high-margin, recurring transaction and clearing revenue with leadership across interest rates, equity indexes, foreign exchange, energy, metals, and commodities, while its 27% stake in S&P Dow Jones Indexes and exclusive role in S&P futures reinforce structural competitive advantages. The business appears to be gaining traction from broadening long-term volume growth, accelerating product velocity, and an increasing international footprint, with September activity showing monthly ADV tracking about 9% above the model and total volumes and open interest rising year over year, which supports the outlook for continued earnings growth and potential upside to consensus. Its history of successful consolidation through the 2007 CBOT Holdings merger, the 2008 Nymex Holdings acquisition, and the 2018 NEX acquisition has expanded its product set into cash foreign exchange, fixed-income trading, and collateral optimization, while climbing daily cross-margin efficiencies and a consistent capital-return profile help offset regulatory and competitive risks.
Bears say
CME Group is viewed negatively because the stock appears to be priced against downside risks that may not be fully offset by the company’s growth profile, with the market still skeptical about volume expansion, regulatory overhangs tied to perpetual futures, and the contribution from new products like prediction markets. Although August volumes reached 29.7M ADV, up 10% month over month and about 6% year over year, and open interest rose to 133.5M with gains in rates, agriculture, metals, and FX, the lower rolling 3M RPC versus forecast suggests monetization could lag even as activity improves. The company’s strong franchises in Russell, Nasdaq-100, and SPX licensing through 2037, 2039, and perpetuity, plus its ~27% stake in S&P DJI and high capital return capacity, do not fully eliminate concerns that FMX is still not gaining meaningful client traction and that incremental growth may be insufficient to justify a constructive view.
This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.
CME Group (CME) Analyst Forecast & Price Prediction
Start investing in CME Group (CME)
Order type
Buy in
Order amount
Est. shares
0 shares